Thrombogenic Potential of Innovia Polymer Valves versus Carpentier-Edwards Perimount Magna Aortic Bioprosthetic Valves

Trileaflet polymeric prosthetic aortic valves (AVs) produce hemodynamic characteristics akin to the natural AV and may be most suitable for applications such as transcatheter implantation and mechanical circulatory support (MCS) devices. Their success has not yet been realized due to problems of calcification, durability, and thrombosis. We address the latter by comparing the platelet activation rates (PARs) of an improved polymer valve design (Innovia LLC) made from poly(styrene-block-isobutylene-block-styrene) (SIBS) with the commercially available Carpentier-Edwards Perimount Magna Aortic Bioprosthetic Valve. We used our modified prothrombinase platelet activity state (PAS) assay and flow cytometry methods to measure platelet activation of a pair of 19 mm valves mounted inside a pulsatile Berlin left ventricular assist device (LVAD). The PAR of the polymer valve measured with the PAS assay was fivefold lower than that of the tissue valve (p = 0.005) and fourfold lower with flow cytometry measurements (p = 0.007). In vitro hydrodynamic tests showed clinically similar performance of the Innovia and Magna valves. These results demonstrate a significant improvement in thrombogenic performance of the polymer valve compared with our previous study of the former valve design and encourage further development of SIBS for use in heart valve prostheses.

[1]  Polymer heart valves. , 1999, The Journal of heart valve disease.

[2]  Alberto Redaelli,et al.  Platelet Activation Due to Hemodynamic Shear Stresses: Damage Accumulation Model and Comparison to In Vitro Measurements , 2008, ASAIO journal.

[3]  J D Hellums,et al.  Red blood cell damage by shear stress. , 1972, Biophysical journal.

[4]  Leonard Pinchuk,et al.  Medical applications of poly(styrene-block-isobutylene-block-styrene) ("SIBS"). , 2008, Biomaterials.

[5]  J. Barry,et al.  In vitro and in vivo evaluation of the safety and stability of the TAXUS® Paclitaxel-Eluting Coronary Stent , 2009, Journal of materials science. Materials in medicine.

[6]  Alexander Kulik,et al.  Mechanical versus bioprosthetic valve replacement in middle-aged patients. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  Siobhain Lynn Gallocher,et al.  Durability Assessment of Polymer Trileaflet Heart Valves , 2007 .

[8]  G. Wilson,et al.  In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. , 2010, Journal of biomedical materials research. Part A.

[9]  G. Grunkemeier,et al.  Durability of pericardial versus porcine aortic valves. , 2004, Journal of the American College of Cardiology.

[10]  J. Vandenbroucke,et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.

[11]  Inger Anne Hagberg, Torstein Lyberg.  Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies , 2000, Platelets.

[12]  Wei Yin,et al.  Flow induced platelet activation in mechanical heart valves - in vitro studies , 2002, Proceedings of the Second Joint 24th Annual Conference and the Annual Fall Meeting of the Biomedical Engineering Society] [Engineering in Medicine and Biology.

[13]  K. B. Chandran,et al.  Towards Non-thrombogenic Performance of Blood Recirculating Devices , 2010, Annals of Biomedical Engineering.

[14]  Danny Bluestein,et al.  Flow-Induced Platelet Activation in Bileaflet and Monoleaflet Mechanical Heart Valves , 2004, Annals of Biomedical Engineering.

[15]  M. J. Dalmau,et al.  The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance. , 2006, Interactive cardiovascular and thoracic surgery.

[16]  Q. Wang,et al.  A novel small animal model for biocompatibility assessment of polymeric materials for use in prosthetic heart valves. , 2009, Journal of biomedical materials research. Part A.

[17]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[18]  D. Bluestein,et al.  Development and Evaluation of a Novel Artificial Catheter-Deliverable Prosthetic Heart Valve and Method for in Vitro Testing , 2009, The International journal of artificial organs.

[19]  J. Jesty,et al.  Reduced-nicotine cigarettes increase platelet activation in smokers in vivo: a dilemma in harm reduction. , 2008, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  Gaetano Burriesci,et al.  Polymeric heart valves: new materials, emerging hopes. , 2009, Trends in biotechnology.

[21]  Leonard Pinchuk,et al.  A novel polymer for potential use in a trileaflet heart valve. , 2006, Journal of biomedical materials research. Part B, Applied biomaterials.

[22]  N. Duraiswamy,et al.  A Phospholipid-modified Polystyrene—Polyisobutylene— Polystyrene (SIBS) Triblock Polymer for Enhanced Hemocompatibility and Potential Use in Artificial Heart Valves , 2009, Journal of biomaterials applications.

[23]  J D Hellums,et al.  Response of human platelets to sheer stress. , 1975, Transactions - American Society for Artificial Internal Organs.

[24]  D. Rubenstein,et al.  Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation , 2009, Platelets.

[25]  T. Treasure,et al.  Heart Valves: Which is the Best Choice? , 1999, Cardiovascular surgery.

[26]  Phillips Re,et al.  Polymer heart valves. , 1999 .

[27]  Shmuel Einav,et al.  The Hemodynamics of the Berlin Pulsatile VAD and the Role of its MHV Configuration , 2006, Annals of Biomedical Engineering.

[28]  Shmuel Einav,et al.  Design Optimization of a Mechanical Heart Valve for Reducing Valve Thrombogenicity—A Case Study with ATS Valve , 2010, ASAIO journal.

[29]  J Jesty,et al.  Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. , 1999, Analytical biochemistry.

[30]  Danny Bluestein,et al.  Flow-induced platelet activation in a St. Jude mechanical heart valve, a trileaflet polymeric heart valve, and a St. Jude tissue valve. , 2005, Artificial organs.

[31]  M. Borger,et al.  Carpentier-Edwards Perimount Magna valve versus Medtronic Hancock II: a matched hemodynamic comparison. , 2007, The Annals of thoracic surgery.

[32]  Shmuel Einav,et al.  Device Thrombogenicity Emulator (DTE)--design optimization methodology for cardiovascular devices: a study in two bileaflet MHV designs. , 2010, Journal of biomechanics.

[33]  J M Anderson,et al.  Directions for improvement of substitute heart valves: National Heart, Lung, and Blood Institute's Working Group report on heart valves. , 1997, Journal of biomedical materials research.

[34]  Danny Bluestein,et al.  The Extent of Platelet Activation under Shear Depends on Platelet Count: Differential Expression of Anionic Phospholipid and Factor Va , 2006, Pathophysiology of Haemostasis and Thrombosis.

[35]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[36]  D. Kereiakes,et al.  Platelet activation and progression to complications. , 2006, Reviews in cardiovascular medicine.